nintedanib + ketoconazole

**Nintedanib + ketoconazole** is a combination of nintedanib, a small molecule tyrosine kinase inhibitor (Ofev), and ketoconazole, an imidazole antifungal agent (Nizoral). Nintedanib targets receptor tyrosine kinases involved in angiogenesis—platelet-derived growth factor receptors (PDGFR), vascular endothelial growth factor receptors (VEGFR), and fibroblast growth factor receptors (FGFR)—and is primarily indicated for idiopathic pulmonary fibrosis and other fibrotic conditions. Ketoconazole, a potent P-glycoprotein (P-gp) and CYP3A4 inhibitor, is added in experimental settings to assess drug-drug interactions, affecting the bioavailability and serum concentration of nintedanib. Co-administration increases nintedanib exposure by inhibiting its P-gp-mediated efflux and CYP3A4 metabolism[1][2][3][4][5].

Other names

nintedanibketoconazole